• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care

July 09, 2026

Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost.

Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy

July 08, 2026

Biosimilar ABP 654 Maintains Efficacy, Safety After Repeated Switching From Ustekinumab

July 07, 2026

Biosimilar Denosumab Matches Reference Drug for Bone Density in Chinese Women

July 06, 2026

Biosimilar Makers Push Forward on Regulatory and Commercial Fronts

July 02, 2026

Featured Content

Positioning Biosimilar Ustekinumab Early Reduces Burden on Spain's National Health System

June 26th 2026

By Skylar Jeremias

Article

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe.

Global Biosimilar Rules Diverge Across WHO Regions, Limiting Patient Access

June 24th 2026

By Skylar Jeremias

Article

Global review reveals uneven biosimilar rules on waivers, interchangeability, and safety tracking—barriers to cheaper biologics and approvals.

Low Biosimilar Awareness in MS Patients Points to Critical Gap in Nurse-Led Education

June 18th 2026

By Skylar Jeremias

Article

Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake.

Biosimilar Expansion, Lower Costs Drive Shift in RA Treatment Guidelines

June 18th 2026

By Skylar Jeremias

Article

New EULAR guidelines speed RA treatment switches as rheumatoid arthritis biosimilars and cost savings push earlier biologics use.

FDA Approves Ranibizumab-hkdz as First Interchangeable, Available in Both Vials and Prefilled Syringes

June 17th 2026

By Cyrus Karkaria, PhD

Article

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

Biosimilar Switching Maintained Disease Control in People With Ankylosing Spondylitis

June 16th 2026

By Skylar Jeremias

Article

Evidence shows biosimilars switching in ankylosing spondylitis maintains disease control with biologics, cuts costs, and highlights nocebo risks.

FDA Approves First Biosimilars Interchangeable With Simponi/Simponi Aria

June 10th 2026

By MHE Staff

Article

Immgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth quarter of this year.

Biosimilar Adoption and Provider Performance in Medicare Value-Based Payment Models

June 9th 2026

By Basit Chaudhry, MD, PhD

Article

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.

FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC

June 8th 2026

By Kennedy Ferruggia

Article

FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.

No Efficacy Loss After Multiple Ustekinumab Biosimilar Switches in Psoriasis

April 2nd 2026

By Giuliana Grossi

Article

Real-world study shows plaque psoriasis stays controlled after 2 ustekinumab biosimilar switches, with stable labs and no serious adverse events.